Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in SARS-CoV-2 experienced versus naïve individuals in the general population - 28/02/23
on behalf of the
Valencian Vaccine Research Program (ProVaVac) study group
Keywords : Covid-19, Neutralizing antibodies, Omicron BA.4/5, SARS-CoV-2, COVID-19 vaccines
Le texte complet de cet article est disponible en PDF.
Members of the Valencian vaccine research program (ProVaVac) study group: Vanaclocha Luna H (General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain); Burks DJ (The Prince Felipe Research Center-CIPF-, Valencia, Spain; Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Comas I (Biomedicine Institute of Valencia, Spanish Research Council (CSIC); Díez-Domingo J (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); Peiro S (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); González-Candelas F (CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain); Ferrer Albiach C (Fundación Hospital Provincial de Castelló);Redón J (INCLIVA Health Research Institute, Valencia, Spain); Sánchez-Payá J (Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, 41,423.Spain; Sanz G (Instituto de Investigación Sanitaria La Fe); Sempere JM (Biotechnology Department, University of Alicante, Spain); Zapater Latorre E (Fundación Hospital General Universitario de València); Navarro D (Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain). |
Vol 86 - N° 3
P. 256-308 - mars 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.